Immune response to FVIII in hemophilia A: an overview of risk factors.
Development of inhibitors is perhaps the most serious complication of factor VIII (FVIII) replacement therapy, which can practically preclude efficient clinical management of patients with hemophilia A. Much effort therefore has been focused both in improving our understanding of the reasons for the formation of FVIII antibodies and to find alternative methods of treatment. Several patient-related factors have been related to the risk of inhibitor development such as ethnicity, FVIII gene mutation type, family history of inhibitors, HLA haplotype, polymorphisms in the promoter regions of IL 10 gene, single nucleotide polymorphisms of tumor necrosis factor alpha gene, and so on. In addition to the genetic determinants, there are several nongenetic factors which mainly include treatment characteristics like the type and purity of coagulation factor concentrates used for treatment, age at the time of initial treatment, initial doses of concentrate, mode of infusion, surgery, frequency of dosing prior to inhibitor development, and intensity of treatment or regular prophylaxis. Inflammatory processes in early childhood are under discussion as being an environmental factor that may modify the immune response to a foreign antigen. The genetic risks cannot be changed, while environmental factors may increase or decrease the inhibitor risk in an individual patient. In addition, there are other causes of inhibitor development against FVIII like stress, age, malignancy, infection, pregnancy, antibiotics, etc. Development of inhibitors in such cases happens in individuals who are not hemophilic and have normal plasma FVIII levels. Acquired inhibitors to FVIII in nonhemophiliacs (autoantibodies) pose a further challenge to treatment, as this is often associated with significant morbidity and mortality. Prognosis in case of autoantibodies is related to the underlying disease process and is associated with high mortality. Improved understanding of these complex interactions may lead to the development of preventive measures to minimize FVIII inhibitor formation. The modifiable risk factors for inhibitor formation may provide the key to predict and perhaps prevent the formation of inhibitors in hemophilia patients.
Ghosh
Kanjaksha
K
National Institute of Immunohaematology, 13th Fl, KEM Hospital, Parel, Mumbai 400012, India. kanjakshaghosh@hotmail.com
Shetty
Shrimati
S
D001323:Autoantibodies / Q000097:blood*; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood* / Q000627:therapeutic use; D018890:Chemoprevention; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology*; D005260:Female; D006239:Haplotypes; D006467:Hemophilia A / Q000188:drug therapy / Q000208:ethnology / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007223:Infant; D008285:Major Histocompatibility Complex / Q000235:genetics; D011247:Pregnancy; D012307:Risk Factors
D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII